| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030-1110; and 2 Kansai Medical University, Moriguchi, Osaka, Japan
Resveratrol (trans-3,4',5-trihydroxystilbene), a recently described grape-derived polyphenolic antioxidant, has been found to protect the heart from ischemic-reperfusion injury. The present study sought to determine the mechanism of cardioprotection by investigating the ability of resveratrol to precondition the heart. Isolated perfused rat hearts were randomly divided into six groups: group I was perfused for 15 min with Kreb-Henseleit buffer (KHB) only; group II was perfused with 10 µM resveratrol; group III was perfused with 10 µM resveratrol plus 100 µM NG-nitro-L-arginine methyl ester (L-NAME), a nonselective nitric oxide (NO) synthase (NOS) inhibitor; group IV was perfused with 10 µM resveratrol plus 100 µM aminoguanidine (AG), an inducible NOS (iNOS) blocker; and groups V and VI consisted of hearts perfused with L-NAME and AG, respectively. The perfusion was then switched to working mode, and all hearts were made globally ischemic for 30 min followed by 2 h of reperfusion. Preconditioning of the hearts with resveratrol provided cardioprotection as evidenced by improved postischemic ventricular functional recovery (developed pressure and aortic flow) and reduced myocardial infarct size and cardiomyocyte apoptosis. Resveratrol-mediated cardioprotection was completely abolished by both L-NAME and AG. In a separate study, hearts were examined for iNOS mRNA induction. Resveratrol caused an induction of the expression of iNOS mRNA beginning at 30 min after reperfusion, increasing steadily up to 60 min of reperfusion, and then decreasing progressively up to 2 h after reperfusion. Preperfusion of the hearts with AG almost completely blocked the induction of iNOS. The results of our study demonstrate that resveratrol can pharmacologically precondition the heart in a NO-dependent manner.
inducible nitric oxide synthase; grapes; wine; antioxidants; polyphenols; heart; ischemia-reperfusion
This article has been cited by other articles:
|
|
 |
|
  I. Moench, H. Prentice, Z. Rickaway, and H. Weissbach Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms PNAS, November 17, 2009; 106(46): 19611 - 19616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Churchill, M.-H. Disatnik, G. R. Budas, and D. Mochly-Rosen Ethanol for cardiac ischemia: the role of protein kinase c Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 469 - 483. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Shinmura, K. Tamaki, and R. Bolli Impact of 6-mo caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxide-dependent increase in nuclear Sirt1 Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2348 - H2355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Opie and S. Lecour The red wine hypothesis: from concepts to protective signalling molecules Eur. Heart J., July 2, 2007; 28(14): 1683 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Juric, P. Wojciechowski, D. K. Das, and T. Netticadan Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2138 - H2143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koneru, S. V. Penumathsa, M. Thirunavukkarasu, S. M. Samuel, L. Zhan, Z. Han, G. Maulik, D. K. Das, and N. Maulik Redox regulation of ischemic preconditioning is mediated by the differential activation of caveolins and their association with eNOS and GLUT-4 Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2060 - H2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Taylor, M. E. Olsen, and J. W. Starnes Improved postischemic function following acute exercise is not mediated by nitric oxide synthase in the rat heart Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H601 - H607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Das and N. Maulik Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., February 1, 2006; 6(1): 36 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kaplan, G. Bisleri, J. A. Morgan, F. H. Cheema, and M. C. Oz Resveratrol, a Natural Red Wine Polyphenol, Reduces Ischemia-Reperfusion-Induced Spinal Cord Injury Ann. Thorac. Surg., December 1, 2005; 80(6): 2242 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaplan, J. A. Morgan, G. Bisleri, F. H. Cheema, H. O. Akman, V. K. Topkara, and M. C. Oz Effects of Resveratrol in Storage Solution on Adhesion Molecule Expression and Nitric Oxide Synthesis in Vein Grafts Ann. Thorac. Surg., November 1, 2005; 80(5): 1773 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Das, S. R. Powell, P. Wang, A. Divald, K. Nesaretnam, A. Tosaki, G. A. Cordis, N. Maulik, and D. K. Das Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H361 - H367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Das, G. A. Cordis, N. Maulik, and D. K. Das Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H328 - H335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Alcendor, L. A. Kirshenbaum, S.-i. Imai, S. F. Vatner, and J. Sadoshima Silent Information Regulator 2{alpha}, a Longevity Factor and Class III Histone Deacetylase, Is an Essential Endogenous Apoptosis Inhibitor in Cardiac Myocytes Circ. Res., November 12, 2004; 95(10): 971 - 980. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
